Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis.
Daclizumab discontinue letter for the US market
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
Development of cladribine at Scripps for hairy cell leukemia and current results.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
Biogen Idec completes purchase of full rights and control of Tysabri®
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
New insights into signaling during myelination in zebrafish.
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Current and future disease-modifying therapies in multiple sclerosis.
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.
Alemtuzumab
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Alemtuzumab for the Treatment of Multiple Sclerosis
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
The immunopathology of multiple sclerosis: an overview.
Withdrawal of the marketing authorization in the European Union
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma.

Pages